Featured Research

from universities, journals, and other organizations

Biomarker panel identifies prostate cancer with 90 percent accuracy

Date:
September 28, 2010
Source:
American Association for Cancer Research
Summary:
Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin.

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin.

The researchers, from Oxford Gene Technology (OGT) and its subsidiary, Sense Proteomic, Ltd., presented their findings at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

"This pilot study shows the potential for a new diagnostic test for prostate cancer. The measure of clinical specificity -- the measure of false positives -- is much improved in this study compared to that seen with the current prostate specific antigen and digital rectal examination test procedures used in diagnosis of prostate cancer," said John Anson, Ph.D., vice president of biomarker discovery at OGT.

Prostate cancer caused an estimated 258,000 deaths worldwide in 2008, and is the second most common cause of cancer deaths in males in the United States with approximately 32,000 deaths estimated for 2010. The most effective screening tests now available are based on a single biomarker, prostate specific antigen (PSA). PSA, however, is known to have a specificity of less than 50 percent, which generates high false positive rates, resulting in many unnecessary surgical and radiotherapy procedures, Anson said.

The researchers developed a "functional protein" microarray to detect autoantibodies in prostate cancer serum samples. By identifying the antigens to which these autoantibodies are raised, these autoantibodies can be used as biomarkers of disease.

Although more commonly linked to autoimmune diseases, the immune system also produces autoantibodies in response to other diseases, including cancer, due to pathological changes that occur during the course of the disease.

"The appearance of autoantibodies may precede disease symptoms by many years," Anson said. "This means that autoantibody-based diagnostic tests can enable presymptomatic and early diagnosis of disease. Early diagnosis of cancer, especially aggressive forms, could significantly increase cure rates."

The researchers developed a microarray of 925 proteins, and then used blood samples to test arrays. They compared the results from 73 samples from patients diagnosed with prostate cancer to 60 samples from a control group of cancer-free individuals to find proteins on the arrays that were bound by autoantibodies present in the blood samples.

Panels of up to 15 biomarkers were identified that distinguished prostate cancer from both benign prostate disease and healthy tissue. The researchers are now testing the biomarker panel in 1,700 samples drawn from prostate cancer patients, cancer-free controls, and patients with other cancers or with other prostate diseases. Identifying prostate cancer from other prostate disease will be the real test of the biomarker panel, according to Anson.

"The latter can present similar symptoms to prostate cancer and can, in many cases, raise PSA levels and trigger a biopsy. OGT expects its biomarker panel to discriminate between prostate cancer and these 'interfering' diseases," said Anson.

In addition to prostate cancer, OGT's "functional protein" microarray can be applied to discover biomarker panels and ultimately develop better diagnostic tests for other cancers and autoimmune diseases. Early results in systemic lupus erythematosus and non-small cell lung cancer are encouraging.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Biomarker panel identifies prostate cancer with 90 percent accuracy." ScienceDaily. ScienceDaily, 28 September 2010. <www.sciencedaily.com/releases/2010/09/100928152012.htm>.
American Association for Cancer Research. (2010, September 28). Biomarker panel identifies prostate cancer with 90 percent accuracy. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2010/09/100928152012.htm
American Association for Cancer Research. "Biomarker panel identifies prostate cancer with 90 percent accuracy." ScienceDaily. www.sciencedaily.com/releases/2010/09/100928152012.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com
What's To Blame For Worst Ebola Outbreak In History?

What's To Blame For Worst Ebola Outbreak In History?

Newsy (July 27, 2014) A U.S. doctor has tested positive for the deadly Ebola virus, as the worst-ever outbreak continues to grow. Video provided by Newsy
Powered by NewsLook.com
Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins